Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. lowered its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 64.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,611 shares of the company’s stock after selling 25,967 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Mineralys Therapeutics were worth $126,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. CWM LLC purchased a new position in shares of Mineralys Therapeutics during the third quarter worth about $25,000. Jump Financial LLC purchased a new position in shares of Mineralys Therapeutics during the third quarter worth about $311,000. FMR LLC grew its holdings in shares of Mineralys Therapeutics by 62.6% during the third quarter. FMR LLC now owns 1,188,653 shares of the company’s stock worth $11,304,000 after buying an additional 457,815 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of Mineralys Therapeutics by 8.3% during the third quarter. Federated Hermes Inc. now owns 22,293 shares of the company’s stock worth $212,000 after buying an additional 1,700 shares during the last quarter. Finally, CHI Advisors LLC purchased a new position in shares of Mineralys Therapeutics during the third quarter worth about $5,405,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group assumed coverage on Mineralys Therapeutics in a report on Tuesday, April 2nd. They set a “buy” rating and a $30.00 price target on the stock. Lifesci Capital reissued an “outperform” rating on shares of Mineralys Therapeutics in a report on Tuesday, March 26th.

Mineralys Therapeutics Trading Down 2.8 %

Shares of MLYS opened at $11.04 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $5.85 and a twelve month high of $17.70. The stock’s 50 day moving average is $13.38 and its two-hundred day moving average is $10.37. The firm has a market capitalization of $547.93 million, a PE ratio of -5.52 and a beta of 2.35.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.24. On average, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -2.44 EPS for the current year.

Insider Transactions at Mineralys Therapeutics

In other news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were acquired at an average price of $13.50 per share, with a total value of $7,499,992.50. Following the purchase, the insider now directly owns 5,074,916 shares of the company’s stock, valued at $68,511,366. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.